Moreover, the extra-pyramidal phenotype of patient II.1, not determined by severe vasculopathy of basal ganglia or by functional alterations, may expand the genetic spectrum of CMT2GG described by [13], potentially implicating this gene in both peripheral neuropathies and parkinsonism, as indicated by other genome-wide association studies [20,21], where other variants in the GBF1 gene have been associated both with Parkinson’s disease and first-degree relation to individuals with Parkinson’s disease. This evidence concerns the gene GBF1 and peripheral neuropathy.